- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00553813
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-based Therapy
Study Overview
Detailed Description
This is a multicenter, open-label, single arm Phase 2 study in patients with advanced, unresectable pancreatic cancer who have received prior gemcitabine-based chemotherapy for their disease. Patients will receive TPI 287 administered as a 60-minute (± 10 min) IV infusion.
The primary endpoint of the trial will be the 6-month survival rate. Additional efficacy endpoints will be response rate, duration of response and stable disease, and 6-month progression free survival. Responses will be assessed by reduction in radiographically measurable disease as defined by the RECIST criteria. Time to worsening of clinical status will be based on reductions in pain and/or analgesic use and changes in tumor markers (CA 19-9) will also be followed.
Patients will remain on study until tumor progression or death, unacceptable toxicity, withdrawal of consent or discontinuation based on Investigator discretion. Patients will be followed for survival for up to 1 year after enrollment on the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28250
- Hospital Madrid
-
-
-
-
California
-
Rancho Mirage,, California, United States, 92270
- Desert Hematology Oncology Medical Group, Inc.
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-1000
- Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University
-
Bethesda, Maryland, United States, 20817
- Center for Cancer and Blood Disorders
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histological or cytological confirmation of ductal adenocarcinoma or undifferentiated carcinoma of the pancreas
- Patients must have metastatic disease precluding curative surgery
- Patients must have received only one prior systemic anticancer treatment for their advanced disease, which must have included a gemcitabine-based therapeutic regimen for advanced disease
- Patients may have received prior adjuvant therapy for their disease
- Patients must have a Karnofsky performance status ≥ 70 (Appendix I)
- Patients must be ≥ 18 years of age
Women of childbearing potential (WOCBP):
- Must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study
- Must have a negative serum or urine pregnancy test
Patients must have adequate organ function:
- Bone marrow reserve as evidenced by: Absolute neutrophil count ≥1,500/uL, Platelet count ≥ 100,000/uL
- Renal function as evidenced by serum creatinine ≥ 2.0 mg/uL
- Hepatic function as evidenced by: Serum total bilirubin < 2.0 mg/uL, SGOT/SGPT < 3X ULN for the reference lab (< 5X ULN for patients with known hepatic metastases)
- Patient must have recovered from prior surgery, radiotherapy or other antineoplastic therapy
- Patients or their legal representative must be able to read, understand, and sign the informed consent to participate in the trial
Exclusion Criteria:
- Patients with islet cell tumors, lymphoma, or sarcoma of the pancreas
- Patients with more than one prior treatment for metastatic pancreatic carcinoma
- Patients with current peripheral neuropathy > Grade 1
- Patients receiving any concurrent chemotherapy, radiotherapy, hormonal therapy or immunotherapy
- Patients with serious infection or a life-threatening illness (unrelated to tumor) that is > Grade 2 NCI CTCAE V 3.0), or active, serious infections requiring parental antibiotic therapy within 4 weeks prior to screening
- History of cardiac disease or events according to the New York Health Association (NYHA) assessments. Clinically evident congestive heart failure as defined by NYHA Class 3 or 4 CHF or cardiac arrhythmia, including atrial fibrillation, if not adequately controlled
- Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results
- Known HIV or Hepatitis B or C (active, previously treated or both)
- A history of other malignancy (except nonmelanoma skin cancer or carcinoma-in-situ of cervix), unless in CR and not receiving therapy for that disease for a minimum of 5 years
- Patients with known hypersensitivity to any of the components of the drugs to be administered on study
- Patients receiving concurrent investigational therapy (investigational therapy is defined as treatment for which there is currently no regulatory authority-approved indication)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Survival
Time Frame: 6 Months
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Response Rate
Time Frame: Ongoing
|
Ongoing
|
Evaluate time to worsening of clinical status as measured by changes in pain, Karnofsky score, and weight.
Time Frame: Ongoing
|
Ongoing
|
Response rates and time to progression of tumor marker levels (CA 19-9)
Time Frame: Ongoing
|
Ongoing
|
Assess the safety and tolerability of TPI 287 in this patient population
Time Frame: Ongoing
|
Ongoing
|
Evaluate outcomes of patient subsets defined by duration of prior gemcitabine therapy
Time Frame: Ongoing
|
Ongoing
|
Evaluate the gene expression profile in relation to clinical outcomes
Time Frame: Ongoing
|
Ongoing
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sandra Silberman, MD, SLS Oncology, LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TPI 287-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on TPI 287
-
Giselle ShollerCortice Biosciences, Inc.TerminatedMedulloblastoma | NeuroblastomaUnited States
-
University of California, San FranciscoTau Consortium; CBD SolutionsCompletedProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Corticobasal Syndrome (CBS) | Primary Four Repeat Tauopathies (4RT)United States
-
University of California, San FranciscoCompletedAlzheimer's DiseaseUnited States
-
Cortice Biosciences, Inc.TerminatedProstate CancerUnited States
-
Giselle ShollerCortice Biosciences, Inc.CompletedMedulloblastoma | Neuroblastoma | RelapseUnited States
-
M.D. Anderson Cancer CenterCortice Biosciences, Inc.Terminated
-
M.D. Anderson Cancer CenterCortice Biosciences, Inc.Withdrawn
-
Cortice Biosciences, Inc.SuspendedGlioblastoma MultiformeUnited States
-
Cortice Biosciences, Inc.TerminatedGlioblastoma MultiformeUnited States
-
Cortice Biosciences, Inc.CompletedNeoplasms | Hodgkin Disease | Non-Hodgkin LymphomaUnited States